Mesoglycan connects Syndecan-4 and VEGFR2 through Annexin A1 and formyl peptide receptors to promote angiogenesis in vitro. by Pessolano, E et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/FEBS.16043
 This article is protected by copyright. All rights reserved
DR ANTONELLO  PETRELLA (Orcid ID : 0000-0002-6945-5295)
Received Date : 18-Feb-2021
Revised Date   : 06-May-2021
Accepted Date : 28-May-2021
Article type      : Original Article
Mesoglycan connects Syndecan-4 and VEGFR2 through Annexin 
A1 and formyl peptide receptors to promote angiogenesis in 
vitro
Emanuela Pessolano1,2, Raffaella Belvedere1, Nunzia Novizio1, Amelia 
Filippelli3, Mauro Perretti2, James Whiteford2, Antonello Petrella1*.
1 Department of Pharmacy, University of Salerno, Fisciano (SA), Italy.
2 The William Harvey Research Institute, Barts and The London School of Medicine 
and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
3 Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi 
(SA), Italy.
*Corresponding author:
Antonello Petrella, Associate Professor; Department of Pharmacy, University of Salerno.










This article is protected by copyright. All rights reserved
e-mail: apetrella@unisa.it
Running Title:  Mesoglycan promotes angiogenesis through SDC4-VEGF-ANXA1 signaling
Abbreviations: GAGs, glycosaminoglycans; SDC4, Syndecan-4; VEGF-A, Vascular Endothelial 
Growth Factor; VEGFR2, Vascular Endothelial Growth Factor receptor-2; EVs, extracellular 
vesicles; ANXA1, Annexin A1; FPRs, Formyl peptide receptors; ECM, extracellular matrix; EC, 
endothelial cell; HUVEC, human umbilical vein endothelial cells; MLEC, primary mouse lung 
endothelial cell; WT, Wild type; Sdc4-/-, Syndecan-4 null mice; EndMT, Endothelial to 
Mesenchymal Transition; siRNA, small interfering RNA; SEM, standard error of mean.
Keywords: Mesoglycan; Vascular Endothelial Growth Factor; Syndecan-4; Annexin A1; 
angiogenesis.










This article is protected by copyright. All rights reserved
Abstract
Mesoglycan is a mixture of glycosaminoglycans (GAG) with fibrinolytic effects and 
the potential to enhance skin wound repair. Here, we have used endothelial cells 
isolated from Wild Type (WT) and Syndecan-4 null (Sdc4-/-) C57BL/6 mice to 
demonstrate that mesoglycan promotes cell motility and in vitro angiogenesis acting on 
the co-receptor Syndecan-4 (SDC4). This latter is known to participate in the formation 
and release of extracellular vesicles (EVs). We characterized EVs released by 
HUVECs and assessed their effect on angiogenesis. Particularly, we focused on 
Annexin A1 (ANXA1) containing EVs, since they may contribute to tube formation via 
interactions with Formyl peptide receptors (FPRs). In our model, the bond ANXA1-
FPRs stimulates the release of vascular endothelial growth factor (VEGF-A) that 
interacts with vascular endothelial receptor-2 (VEGFR2) and activates the pathway 
enhancing cell motility in an autocrine manner, as shown by Wound-Healing/invasion 
assays, and the induction of Endothelial to Mesenchymal Transition (EndMT).
Thus, we have shown for the first time that mesoglycan exerts its pro-angiogenic 
effects in the healing process triggering the activation of the three interconnected 
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1. Introduction
Mesoglycan represents a potential therapy for augmenting the healing of skin 
lesions. This GAG mixture can promote angiogenesis in vitro, improving the generation 
of capillary- like structures essential for wound repair process [1]. Angiogenesis is 
fundamental in many physiological and para-physiological processes, and in the 
context of skin lesions it plays a key role in providing the tissue with the necessary 
nutrients [2]. During this process, endothelial cells undergo the Endothelial-to-
Mesenchymal Transformation (EndMT). This is a mechanism in which cells are 
transformed from endothelial to mesenchymal phenotype as evidenced by loss of 
endothelial cell (EC) junctions, down-regulation of endothelial markers and concomitant 
up-regulation of mesenchymal markers leading to the acquisition of migratory 
properties favouring angiogenesis [3]. During wound healing, angiogenic capillaries 
infiltrate in the extracellular matrix (ECM). These cells arrange themselves into a 
microvascular network, produce granulation tissue [4], and lead to wound resolution 
resulting in healthy new skin. The formation of new vessels has a pivotal role in wound 
repair because the most common causes of the formation of chronic injuries are a poor 
perfusion of the wound which leads to a diminished bioavailability of growth factors and 
receptors and a decreased proliferative potential of the cells at the injury site [5].
Vascular endothelial growth factors (VEGF-A) promote several steps of wound 
healing such as collagen deposition, angiogenesis and epithelization [6]. There are five 
different isoforms of VEGF: VEGF-A (VEGF165) VEGF-B, VEGF-C, VEGF-D and PLGF. 
Among these isoforms, VEGF-A165 is the most significant and it binds to both vascular 
endothelial growth factor receptors VEGFR-1 and VEGFR-2 [7]. The engagement 
VEGF-A with VEGFR2 triggers numerous pro-angiogenic pathways in ECs including 
the stimulation of vascular permeability, the loss of connections between endothelial 
cells and migration [8].
AnnexinA1 (ANXA1) and its mimetic N-terminal peptide Ac2-26 has caused 
considerable interest for its role in promoting angiogenesis [9 - 11]. Our research has 
highlighted that secreted ANXA1 contained within extracellular vesicles (EVs) stimulate 
the formation of capillary-like structures in vitro [12]. Of relevance, the interaction 
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containing ANXA1 in human keratinocytes [13, 14], and is potentially a paracrine way 
in which HUVEC tubulogenesis can be promoted [15].
Here we explore, for the first time, the effects on endothelial cells of mesoglycan-
VEGF, investigating the association of two molecules that independently augment 
wound healing and are pro-angiogenic. This study aims to understand the link between 
mesoglycan/SDC4 and VEGF-A/VEGFR2 to establish connections between these two 
different pro-angiogenic pathways.
2. Results
2.1. Mesoglycan and VEGF-A in concert promotes angiogenesis in vitro
Angiogenesis is the process that creates new blood vessels and plays a key role in 
wound repair [14]. Cell migration is an important angiogenic process and we tested the 
effect of mesoglycan and VEGF-A, a potent angiogenic factor, alone and in 
combination on the migratory properties of HUVECs using a scratch wound assay. As 
expected, treatment with VEGF-A or mesoglycan lead to increased EC migration. 
Representative images of wound healing assay on HUVEC cells are reported in figure 
1 A, and surprisingly, effect on motility was increased further when both mesoglycan 
and VEGF-A were used in combination (Fig. 1A and B). We next evaluated the effects 
of mesoglycan and VEGF-A on micro-capillary formation in presence of matrigel. In 
common with the scratch wound assays, both VEGF-A and mesoglycan treatment lead 
to the formation of significantly longer and more branched tubules as compared with 
the untreated control. These parameters were enhanced further when treated with 
VEGF-A and mesoglycan in combination, as shown in figure 1 C-E.
2.2. The association of mesoglycan and VEGF-A activates the VEGFR2 pathway 
in HUVEC cells
To explore the effect of mesoglycan and VEGF-A in combination in stimulating 
angiogenesis, we explored the impact of these treatments on VEGFR2 signalling and 
effectors downstream of this receptor. Figure 2 showed that the treatment of HUVECs 
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expression levels of VEGFR2. Engagement of VEGRF2 with VEGF-A leads to the 
phosphorylation of a number of Tyr residues in its cytoplasmic domain. Phosphorylation 
of Tyr951 is intimately associated with EC migration [8]. Phosphorylation of this residue 
was comparable to controls when HUVECs were treated with mesoglycan alone, 
however as expected VEGF-A treatment resulted in an increase in phosphorylation of 
Tyr951 and this effect was even greater when mesoglycan and VEGF-A were used in 
combination. Which is suggestive of a role for mesoglycan in promoting the interaction 
between VEGF-A and VEGFR2.
We next looked at the phosphorylation status of several downstream kinases of 
VEGFR2 which are known to be phosphorylated in response to VEGF-A. These 
included, Extracellular-signal-regulated kinases (ERK), p38 mitogen-activated protein 
kinases (p38MAPK), heat shock protein 27 phosphorylation (p-HSP27), and Focal 
adhesion kinase (FAK). In all instances, phosphorylation was substantially more when 
mesoglycan and VEGF-A were used in concert. As reported in the western blot in 
figure 2 A and confirmed in the relative intensity analysis in figure 2 B, no significant 
difference appeared in ERK expression between the treatments. In contrast, there was 
a positive regulation of p-ERK in HUVEC treated with mesoglycan and VEGF-A 
separately, but particularly when these two components were co-administered. The 
same trend occurred for the expression levels of p38MAPK and p-HSP27. p38MAPK-
HSP27 signalling downstream VEGF-A-VEGFR2 contributes to actin cytoskeleton 
reorganization and migration of endothelial cells to promote pro-angiogenic effects [16]. 
FAK and its phosphorylated form (p-FAK) are proteins downstream VEGFR2 pathway, 
involved focal adhesions and stress fiber development. The co-administration of 
mesoglycan and VEGF promoted higher expression levels of FAK, and this was also 
reflected in an increase in p-FAK. Interestingly, administration of VEGF-A and 
Mesoglycan alone could promote this increase in FAK levels (Fig. 2A-B).
Immunofluorescence analysis revealed that internalization of p-VEGFR2 after 24 
hours of VEGF-A treatment and this was enhanced by co-administration with 
mesoglycan (Fig. 2C panels a-d). The quantification of the fluorescence intensity of p-
VEGFR2 shown in figure 2 (panels a-d) is reported in supplementary figure S panel A. 
Loss of VE-cadherin is associated with VEGF-A promoted EndMT [17] and we 
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VEFA and mesoglycan (Fig. 2C panels e-h and Fig. 2D). The corresponded to an 
increase in the formation of stress fibers observed through the polymerization of F-actin 
(Fig. 2C panels i-l) and FAK positive focal adhesions (Fig. 2C panels m-p). This data 
can be further appreciated in figure 2D.  These results confirm t h a t  mesoglycan in 
concert with VEGF-A leads to enhanced angiogenic responses and this is due to 
enhanced signalling through the VEGF-A/VEGFR2 axis.
2.3. Syndecan-4 is required for mesoglycan-VEGF-A pro-angiogenic responses 
in vitro
Our published study [14] describes how mesoglycan can stimulate syndecan-4 
pathway and promote the migration in human keratinocytes during wound repair 
process. 
Recent evidence shows that SDC4 plays a key role in the regulation of cell 
migration. Analyses carried out on myoblasts show how, following the silencing of 
SDC4, the migration speed is strongly reduced [18]. Given the ubiquitous expression of 
SDC4, these results are potentially relevant to other cell types, such as in 
keratinocytes, as we have shown previously [14].
Moreover, mice null for SDC4 exhibit wound defects, particularly in the formation of 
granulation tissue in which angiogenesis is impaired and in wound closure [19]. Based 
on this we speculated it may have a role in the synergistic effects of mesoglycan-
VEGF-A on angiogenesis.
We therefore performed scratch wound migration assays on primary mouse lung 
endothelial cells from WT and Sdc4-/- animals. WT primary mouse lung endothelial cell 
(MLECs) had the same response profile we observed in HUVECs, in that co-
administration of VEGF-A and mesoglycan significantly increased EC migration.
In contrast, the absence of SDC4 lead to reduced EC migration in response to all 
treatments (Fig. 3A-B), suggesting a role for this proteoglycan in both VEGF-A and 
mesoglycan driven responses. These results were mirrored when tubule formation in 
response to matrigel was assayed. WT MLECs showed enhanced response to VEGF-A 
and mesoglycan and this was enhanced when the two were combined. In all instances 
SDC4 showed a lack response (Fig. 3C-E).
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pathways stimulated by VEGF-A and mesoglycan.
2.4. Syndecan-4 has a role in mesoglycan-VEGF-A-VEGFR2 pathway
Having confirmed the pro-angiogenic effects that mesoglycan-VEGF-A exert on WT 
and not on Sdc4-/- MLECs we sort to determine whether genetic ablation of SDC4 had 
any impact on VEGF-A/VEGFR2 signalling. WT and Sdc4-/- MLECs had equivalent 
levels of VEGFR2 regardless of the treatments. Additionally, measurement of Tyr951 
phosphorylation on VEGFR2 in WT MLECs broadly reflected the situation observed on 
HUVECs in that VEGA treatment alone and in combination elicited more VEGFR2 
phosphorylation. Levels of VEGFR2 phosphorylation was at a lower level in Sdc4-/- 
MLECs however VEGF-A treatment did elicit a phosphorylation response. Of note 
combined treatment of Sdc4-/- MLECs with mesoglycan and VEGF-A lead to a 
reduction in VEGFR2 phosphorylation. VEGF-A alone or with mesoglycan administered 
to WT MLECs stimulated an increase in ERK and p-ERK levels. In Sdc4-/- MLECs, ERK 
levels of expression remained similar to the untreated control, while its phosphorylated 
form increased only in presence of VEGF-A alone. In addition, increases in p38MAPK 
and p-HSP27 were not evident in Sdc4-/- cells, while in WT cells their phosphorylation 
increased following VEGF-A and mesoglycan- VEGF-A treatment in concert. FAK and 
p-FAK in WT MLECs appeared upregulate particularly after VEGF-A and mesoglycan-
VEGF treatment, on the contrary, MLEC Sdc4-/ did not show a significant alteration, 
except for VEGF (Fig. 4A-B). The optical density of all the protein bands detected by 
Western blot in figure 4A is reported in figure 4B.
We next observed via confocal microscopy the localization of proteins involved in 
EndMT. For p-VEGFR2, WT cells presented the same trend previously observed in 
HUVECs. However, as shown in figure 4D, in Sdc4-/- cells the fluorescence intensity of 
p-VEGFR2 was lower than in WT cells (Fig. 4C panels a-h) and its expression level 
increased only in presence of VEGF-A (Fig.  4C panel g). VE-cadherin was clearly 
visible at the leading edge of WT MLECs only in the untreated control (Fig. 4C panel i) 
and disappeared with all treatments (Fig. 4C panels j-l). On the contrary, in Sdc4-/- 
MLECs, we found a slight decrease of this protein only in presence of VEGF-A (Fig. 4C 
panels m-p). The quantification of the fluorescence intensity of VE-cadherin is shown in 
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panels u-x) as opposed to WT ones. Furthermore, in the latter, actin filaments appeared 
well organized with mesoglycan, VEGF-A and mesoglycan- VEGF-A treatments (Fig. 
4C panels r-t). Comparing FAK expression between WT and Sdc4-/- EC, the reduction 
of focal adhesions was clearly visible in absence of the proteoglycan (Fig. 4D). FAK 
appeared as clusters at the boundary of WT MLECs treated with mesoglycan and 
VEGF-A (Fig. 4C panels z-a’), but particularly when combined (Fig. 4C panel b’). In 
contrast, its expression in Sdc4-/- cells was similar to the untreated control of WT cells 
(Fig. 4C panel c’), except for the treatments with VEGF-A (Fig. 4C panel e’). 
Taken together these results showed that mesoglycan act as a bridge among SDC4 
and VEGF-A-VEGFR2 pathway.
2.5. Annexin A1 is the link between Syndecan-4 and VEGFR2
In order to better understand the connection, promoted by mesoglycan, between 
SDC4 and VEGFR2 in enhancing angiogenesis in vitro, we investigated the protein 
AnnexinA1 (ANXA1) as a key regulator of angiogenesis both in pathological and 
physiological environment [12, 15, 20].
Here, we found an increase of this protein in WT MLECs and HUVECs treated with 
mesoglycan, compared to Sdc4-/- cells that presented a small significant rise of ANXA1 
only in VEGF-A treatment (Fig. 5A-B). Based on this, our strategy was to treat HUVECs 
with small interfering RNA (siRNA) against ANXA1 (siANXA1), by which we obtained a 
significant decrease in ANXA1, as reported in figure 5 A-B. We next performed 
functional experiments on HUVECs using siANXA1 in presence or absence of 
mesoglycan, VEGF-A and in combination. Interestingly, migration and micro-capillary 
formation in vitro were reduced when ANXA1 had been knocked down in HUVECs 
(Fig. 5C-G).
From the recent literature [9], we know that the ANXA1-FPRs binding stimulates the 
externalization of VEGF. For this reason, we hypothesized that the increase of ANXA1 
in HUVEC cells treated with mesoglycan was able to promote the subsequent 
externalization of VEGF-A and facilitate the motility. We have revealed via Western blot 
the presence of VEGF-A in HUVECs supernatant, particularly when treated with 
mesoglycan (Fig. 5H). To validate the purity of the analysed supernatants, and the 
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used for normalization. The different levels of VEGF-A in HUVEC supernatants have 
been further revealed by the ELISA (enzyme-linked immunosorbent assay). Thus, the 
histogram in Fig. 5I confirmed the high degree of externalization of VEGF-A in 
presence of mesoglycan whose action was notably reduced when ANXA1 expression 
was decreased by siRNA. 
Together, these results provide important insights into the role of ANXA1 as a 
mediator of angiogenesis promoted by the combination of mesoglycan and VEGF-A.
2.6. Annexin A1 is released from extracellular vesicles in HUVEC cells treated 
with mesoglycan
In our previous work we have shown that ANXA1 participates in extracellular vesicle 
(EVs) biogenesis and forms part of their cargo [12, 13]. We started out to observe 
whether mesoglycan stimulated the release of EVs containing ANXA1 from HUVECs. 
EVs isolated from HUVECs treated with mesoglycan (EVs mesoglycan) and from the 
same untreated cells (EVs ctrl) were purified through a serial centrifugation and their 
quantity and size were measured using nanoparticle tracking analysis. EVs mesoglycan 
(green line in Fig. 6A) showed a significant increase in number compared with EVs ctrl 
(red line in Fig. 6A). The range of the vesicles was from ~50 nm to 630 nm, with a 
majority of vesicles in the range of 80 to 150 nm for both the groups (Fig. 6A). This 
enrichment of EVs between 80-150 nm corresponded with the subclass of nano-
vesicles classed as exosomes. To confirm this data, we tested the two groups of 
vesicles by Western blot using CD63 and CD81 as specific exosomal markers [21]. As 
reported in figure 6 B, the expression of CD81 and CD63 was evident only in EV 
samples and not in HUVECs total lysates. Moreover, the amount of CD81 and CD63 
was higher in EVs released in response to mesoglycan, supporting the previous 
analysis obtained via nanoparticle tracking analysis. We also observed the significant 
externalization of ANXA1 through EVs mesoglycan, particularly as cleaved form, 
compared with EVs ctrl (Fig. 6B).
Therefore, mesoglycan promotes a consistent externalization of ANXA1 through EVs.
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In [13] we highlighted the autocrine loop ANXA1/EVs/FPRs induced by mesoglycan 
in keratinocytes. Based on this, we investigated the hypothetic role of the same loop in 
HUVECs in promoting angiogenesis. HUVEC migration was significantly enhanced with 
mesoglycan elicited EVs compared with the untreated control (Fig. 7A-B). By utilizing 
BOC1 at a concentration of 100 µM to block both FPR1 and FPR2 (respectively 
receptors for and N-terminal mimetic peptide [22] and ANXA1 [23]), we studied the role 
of ANXA1 containing EVs. Surprisingly, in presence of the pan-antagonist BOC1 
HUVEC cell motility was reduced.
We next evaluated the effects of ANXA1 in EVs promoting angiogenesis performing 
in vitro tests of capillary structures. As already seen for migration assay, also in this 
second process the ability of EVs to stimulate the formation of vessels was confirmed. 
Notably EVs mesoglycan promoted a significant number of branching points and the 
relative tube length compared to EVs ctrl and untreated control. On the contrary, by 
blocking FPRs these effects were reverted, although the same trend of the 
experimental points without BOC1 was maintained (Fig. 7C-E).
The results in this section suggested that mesoglycan-induced ANXA1/EVs/FPRs 
loop promotes angiogenesis in HUVECs.
2.8. EVs containing ANXA1 promote angiogenesis in a FPRs dependent manner
After evaluating that EVs promoted functional effects on motility in autocrine ANXA1- 
FPRs dependent manner, we investigated EndMT process in absence of ANXA1 by 
confocal microscopy. First, as schematized in the histograms in figure 8B, we found that 
VE-cadherin expression was significantly reduced in HUVECs treated with EVs ctrl and 
EVs mesoglycan compared to the untreated control (Fig. 8A panels a-c). On the 
contrary, in presence of BOC1, this adhesion molecule was visible in the cell junctions, 
even in presence of the two groups of vesicles (Fig. 8A panels d-f). Based on the 
variation of HUVECs migration speed, we observed well organized stress fibers in cells 
treated with mesoglycan EVs (Fig. 8A panels g-i). This cytoskeletal reorganization was 
not observed when FPRs were blocked (Fig. 8A panels j-l). Moreover, the considerable 
presence of FAK clusters was influenced by the treatment with EVs. This phenomenon 
was greatly reduced following the addition of BOC1 (Fig. 8A panels s-x and Fig. S 
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by the secretion of ECM proteins such as fibronectin which supports the elongation of 
the vessels in vitro [24]. We found a strong and structured expression of fibronectin in 
presence of both types of EVs (Fig. 8A panels m-o). On the contrary, fluorescence 
intensity levels were significantly reduced when FPRs were blocked in HUVEC cells in 
vitro (Fig. 8A panels p-r). The quantification of the fluorescence intensity of the 
fibronectin shown in figure 8A is reported in figure 8B.
Finally, EVs mesoglycan are able to enhance the angiogenesis on HUVECs 
promoting EndMT.
3. Discussion
Numerous studies have explored the use of mesoglycan for treatment of vascular 
disease and its efficacious anti-thrombotic and fibrinolytic effects [15, 25, 26, 28]. We 
have established the significant in vitro impact of mesoglycan in skin wound repair. 
Mesoglycan is a mixture of GAGs that activate several of the cell types involved in skin 
regeneration, these include keratinocytes, fibroblasts, and endothelial cells. 
Mesoglycan accelerates healing and promotes the formation of granulation tissue, 
stimulating migration and differentiation of keratinocytes, fibroblast activation and 
angiogenesis [1, 27].
In order to heal the wounds correctly, the formation of new blood vessels from the 
pre-existing vascular system is essential. Endothelial cells, after injury, are stimulated 
and activated by various pro-angiogenic factors, including VEGF-A [5]. In healthy skin, 
this growth factor is not highly expressed, however, skin injury causes a marked VEGF 
increase with consequent angiogenesis [28].
In this study we demonstrate a synergistic effect between mesoglycan and VEGF-A 
which enhances the pro-angiogenic stimuli necessary for wound repair. In HUVECs and 
aortic ring explants we found that administration of mesoglycan-VEGF-A promotes EC 
migration, tube formation and sprouting compared to a greater extent than the two 
components individually. The use of mesoglycan and VEGF-A in combination also 
resulted significantly more stimulation of VEGFR2 related signalling pathways that 
promote angiogenic processes such as cell survival, vascular permeability, 
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mesoglycan-VEGF-A phosphorylation of several proteins such as p-ERK, p38-MAPK 
and p-HSP27 is increased. These proteins are important for the actin polymerisation 
[16] and FAK activation necessary for focal adhesion turnover and regulation of 
migration [29] supporting cell motility.
Our previous studies have highlighted that the mechanism of action of mesoglycan on 
keratinocytes involves SDC4 [13, 14], a membrane proteoglycan that is also of 
significant importance in angiogenesis [19]. 
SDC4 influences the polarization of myoblasts during migration [18], and the reduced 
motility of SDC4-deficient cells can affect various cell lines such as fibroblasts [30], 
hepatic stellate cells [31], and endothelial cells [32]. Endothelial cells from Sdc4-/- mice 
exhibited reduced cell migration as compared to WT supporting the hypothesis that it is 
involved in the pro- angiogenic effects elicited by the co-administration of mesoglycan-
VEGF-A in vitro. Obviously, we did not expect the total deprivation of motility in the 
absence of SDC4, as other pathways can intervene in compensating for the deficiency, 
one among many the one mediated by VEGFR2. VEGFR2 phosphorylation in response 
to mesoglycan and VEGF-A was considerably reduced, and analysis of downstream 
cellular events such as the redistribution of [33], FAK activation [34] and cytoskeletal 
remodelling [35] revealed that these were also reduced. Interestingly mesoglycan alone 
cannot stimulate any of these pathways.
Prior studies have described the involvement of ANXA1 protein in promoting 
angiogenesis [11, 12, 15, 20], and we observed an increase of the level of this protein 
in cells treated with mesoglycan. Hence, to comprehend the role of ANXA1 in our 
system, we performed functional experiments on HUVEC cell motility by reducing the 
levels of available ANXA1 using siRNA. Our results showed that with low levels of the 
protein, endothelial cell motility and tube formation are not promoted, confirming the 
fundamental role of this protein in angiogenesis. 
SDC4 participates to the formation and secretion of EVs [37] and these vesicles may 
contribute to wound healing [13, 15]. Our previous studies have shown that 
keratinocytes treated with mesoglycan secreted a large amount of EVs contained 
ANXA1 in the extracellular environment and promoted angiogenesis in vitro [13, 15]. 
Based on this we speculated that ANXA1 + EVs could be a link between SDC4 and 
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number of ANXA1 + secreted vesicles as was the case with keratinocytes, and we 
confirmed that this occurred FPRs. We assumed an interaction between ANXA1 and its 
receptor, just as already demonstrated [13]. This was later confirmed using BOC1 
molecule as a pan-antagonist of FPRs [38]. Indeed, EVs containing ANXA1 can further 
promote the angiogenic effect of mesoglycan in an autocrine way, but in presence of 
BOC1, at a concentration of 100 µM namely able to block FPR-1 and FPR-2, the 
effects on this process were not significant. This finding suggests, for the first time, that 
the interaction between vesicles and endothelial cells occurs through the ANXA1-FPRs 
interaction promoting motility and angiogenesis in an autocrine manner, following 
mesoglycan treatment. 
ANXA1-FPR2 binding can control VEGF-A secretion in uterine cells [9]. We 
analysed whether mesoglycan induced secretion of ANXA1 and its interaction with 
FPRs could promote the externalisation of VEGF-A. Analysing via western blot the 
supernatant from HUVEC cells treated with mesoglycan, we observed the significant 
presence of VEGF-A compared with the untreated cells. Moreover, this growth factor is 
not secreted in the absence of ANXA1, confirming the needs of this protein to promote 
the externalisation of VEGF-A.
The involvement of ANXA1 in VEGF-A release was already demonstrated in another 
model. Indeed, cardiac macrophages from ANXA1-KO mice are unable to release 
VEGF-A, instead, when these mice treated with ANXA1 showed high amounts of 
VEGF-A released from cardiac macrophages [39].
Taken together, our data confirm the positive effects of mesoglycan on angiogenesis 
stimulation in vitro and allowed us to hypothesise a novel mesoglycan-promoted 
mechanism. We highlighted the ability of mesoglycan to trigger the activation of three 
different pathways that convey in HUVEC cells activation. (I) Mesoglycan interacts with 
the co-receptors SDC4 and stimulates the expression of EndMT markers, endothelial 
cell motility and the production of ANXA1-containing vesicles. (II) These vesicles are 
then externalised and interact in an autocrine manner with FPRs, amplifying the 
activation of endothelial cells. (III) The ANXA1-FPRs interaction results promoting the 
externalisation of VEGF-A, which in turn stimulates the VEGR2 further supporting 
angiogenic processes.
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unanswered question, so this aspect requires further investigation. A more in-depth 
study will be dedicated to the interaction between ANXA1 contained in EVs and FPRs, 
to understand if through this bond it allows the vesicles to be internalized by the receptor 
cells. Moreover, our future perspective is to validate the use of mesoglycan as potential 
drug triggering pro-angiogenic effects on blood dermal microvascular cells before 
translating the research on in vivo models.
4. Material and methods
4.1. Cell culture and mesoglycan preparation
HUVECs were purchased from American Type Culture Collection (ATCC, Manassas, 
VA, USA) (ATCC® PCS-100-010™) and maintained as reported in [1]. Briefly, cells 
were maintained at 37°C in 5% CO2 −95% air humidified atmosphere and were serially 
passed at 70–80% confluence. Cells cultured until passage 10.
MLEC from WT and Sdc4-/- were isolated form Wild‐type and syndecan-4-null 
C57BL6 mice (4–6 week-old females) obtained from Charles River Laboratories (UK), 
and kept under pathogen-free conditions in the Animal Facility of the Queen Mary 
University of London for 7 days of acclimatisation. All experiments were approved in 
accordance with UK Home Office regulations, under the UK legislation for the 
protection of animals. Wild-type and syndecan-4-null mice were sacrificed by cervical 
dislocation and lungs were excised and minced with a scalpel for 5 minutes. The lung 
fragments were digested with collagenase (Life Technologies, Carlsbad, California, 
USA) for 1 hour at 37◦C. then transferred in a petri dish containing 10mL of MLEC 
medium (40% Dulbecco's modified Eagle's low glucose medium (DMEM, Life 
Technologies, Carlsbad, California, USA), 40% Hams F-12 Medium (Life Technologies, 
Carlsbad, California, USA), Endothelial Growth Supplement (Sigma Aldrich, St. Louis, 
MO, USA) and 20% of heat inactivated foetal calf serum (Invitrogen, Carlsbad, 
California, USA). The resulting solution was disaggregated by aspiration through a 19.5-
gauge needle for 4 times. The resulting cell suspension was filtered with a 70 μm filter 
and then centrifuged at 1200 RPM for 5 minutes. The resultant cell pellet was 
resuspended in MLEC medium and plated on flasks coated with a mixture of 0.1% 
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Massachusetts, USA) and 30 μg/ml collagen (Advanced Biomatrix, Sea Lion Pl, 
Carlsbad, CA, USA). After 24 hours the media was refreshed. After one week the 
endothelial cells were purified by a positive (ICAM-2; BD Pharmingen, Franklin Lakes, 
NJ, USA) cell sort using anti-rat IgG-conjugated magnetic beads (Dynal, Wiltshire, UK).
Mesoglycan is a natural GAG preparation extracted from porcine intestinal mucosa 
and is composed of heparan sulfate (47.5%), dermatan sulfate (35.5%), slow-moving 
heparin (8.5%) and condroitin sulfate (8.5%) [27]. Powder of sodium salt mesoglycan 
was kindly provided by Laboratori Derivati Organici (LDO) S.p.a. (Trino, Italy) and 
dissolved in the cell medium at an initial concentration of 1 mg/ml, as previously 
reported [14, 27]. Mesoglycan administration was established in a dose of 300 μg/ml for 
all performed experiments.
4.2. In vitro Wound-Healing assay
HUVEC and MLEC cells were seeded in a 12-well plastic plate at 5 × 105 cells per 
well. After 24 hours incubation, cells reached 100% confluency and a wound was 
handmade produced in the middle of the monolayer by gently scraping the cells with a 
sterile plastic p10 pipette tip to create a wound area of about 500 μm. After removing 
incubation medium and washing with PBS, cell cultures were incubated in the presence 
of mesoglycan (0.3 mg/mL, LDO, Laboratori Derivati Organici spa, Trino, Italy), VEGF 
(10ng/mL, VEGF- 165 recombinant human for HUVEC cells and VEGF-164 
recombinant mouse for MLEC, R&D Systems, Minneapolis, Minnesota, USA), BOC1 
(100 μM, Bachem AG, Bubendorf, Switzerland) and/or EVs ctrl (1x106) and EVs 
mesoglycan (1x106), both isolated from HUVEC. All experimental points were further 
treated with mitomycin C (10 μg/ml, Sigma Aldrich, St. Louis, MO, USA) to ensure the 
block of mitosis. The wounded cells were then incubated at 37 °C in a humidified and 
equilibrated (5% v/v CO2) incubation chamber of an Integrated Live Cell Workstation 
Leica AF-6000 LX (Leica Microsystems, Wetzlar, Germany). A 10 × phase contrast 
objective was used to record cell movements with a frequency of acquisition of 10 
minutes on at least 10 different positions for each experimental condition. The 
migration rate of an individual cell was determined by measuring the distances covered 
from the initial time to the selected time-points. Particularly, the analysis was performed 
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movement highlighted by the sequence of the images taken by the microscope during 
the experimental time. The distance travelled by the single cell under examination 
between one side of the scratch and the other can be measured using Leica ASF 
software (bar of distance tool, Leica ASF software, version Lite 2.3.5, Leica 
microsystem CMS Gmvh).
4.3. Tube formation assay
A 24-well plate was coated with Matrigel (Becton Dickinson Labware, Franklin Lakes, 
NJ, USA) mixed to EGM-2 1:1 for HUVEC cells and MLEC medium 1:1 for MLEC WT 
and Sdc4-/- on ice and incubated at 37°C for 30 minutes to allow gelation to occur. The 
cells were seeded to the top of the gel at a density of 2 × 104 cells/well in presence or 
not of the treatments. Cells were incubated at 37°C with 5% CO2. After 12 hours, 
pictures were captured using EVOS® light microscope (10 ×) (Life technologies 
Corporation, Carlsbad, CA, USA). The length of each tube was measured, and the 
number of branches was calculated using ImageJ (NIH, Bethesda, MD, USA) 
(Angiogenesis Analyzer for ImageJ) software.
4.4. Western blot
Protein expression was examined by SDS-PAGE, as described in [40]. Briefly, total 
intracellular proteins were extracted from the cells by freeze/thawing in lysis buffer 
containing protease inhibitors. Protein content was estimated according to Biorad 
protein assay (BIO-RAD). A total of 20 µg of proteins were analysed using the 
chemioluminescence detection system (Amersham biosciences; Little Chalfont, UK) 
after incubation with primary antibodies against VEGFR2 (rabbit polyclonal; 1:10000; 
Cell Signaling Technology, Danvers, Massachusetts, USA), p-VEGFR2 (rabbit 
monoclonal; (Tyr951); 1:500; Cell Signaling Technology, Danvers, Massachusetts, 
USA), ERK (rabbit monoclonal; 1:1000; Cell Signaling Technology, Danvers, 
Massachusetts, USA), p-ERK (rabbit monoclonal; 1:1000; (Thr202/Tyr204); Cell 
Signaling Technology, Danvers, Massachusetts, USA), p38MAPK (rabbit monoclonal; 
1:1000; Cell Signaling Technology, Danvers, Massachusetts, USA); p-HSP27 (rabbit 
monoclonal; S78; 1:250; Cell Signaling Technology, Danvers, Massachusetts, USA); 
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USA); p-FAK (rabbit monoclonal; (Tyr397) 1:1000; Cell Signaling Technology, Danvers, 
Massachusetts, USA); VEGF (rabbit polyclonal; 1:100; Santa Cruz Biotechnologies; 
Dallas, TX, USA); ANXA1 (rabbit polyclonal; 1:10000; Invitrogen; Carlsbad, CA, USA); 
CD81 (mouse monoclonal; 1:500; BD Pharmingen, Franklin Lakes, NJ, USA); CD63 
(mouse monoclonal; 1:500; BioLegend; San Diego, CA); GAPDH (rabbit monoclonal; 
1:1000 Cell Signaling Technology, Danvers, Massachusetts, USA); β-actin (mouse 
monoclonal; 1:1000; Santa Cruz Biotechnologies; Dallas, TX, USA). The blots were 
exposed to Las4000 (GE Healthcare Life Sciences) and the relative band intensities 
were determined using ImageQuant software (GE Healthcare Life Sciences).
4.5. Confocal Microscopy
After the specific time of incubation, HUVEC and MLEC WT and SCD4-KO were 
fixed in p-formaldehyde (4% v/v with PBS) for 5 minutes, permeabilized in Triton X-100 
(0.5% v/v in PBS) for 5 minutes, and then incubated in goat serum (20% v/v PBS) for 
30 minutes. Then cells were incubated with antibody anti p-VEGFR2 (rabbit 
monoclonal; (Tyr951); 1:100; Cell Signaling Technology, Danvers, Massachusetts, 
USA); VE-cadherin (rabbit polyclonal; 1:100; Cambrige, UK); FAK (rabbit monoclonal; 
1:1000; Cell Signaling Technology, Danvers, Massachusetts, USA); fibronectin (mouse 
monoclonal, 1:100; Abcam, Cambrige, UK), overnight at 4°C. After 2 washing steps, 
cells were incubated with anti-rabbit and/or anti-mouse AlexaFluor (488 and/or 555; 
1:1000; Molecular Probes) for 2 hours at RT. Other cells were incubated with FITC-
conjugated anti-F-actin (5 µg/mL; Phalloidin-FITC, Sigma- Aldrich) for 30 minutes at RT 
in the dark. To detect nucleus, samples were excited with a 458 nm Ar laser. A 488 nm 
Ar or a 555 nm He-Ne laser was used to detect emission signals from target stains. 
Samples were vertically scanned from the bottom of the coverslip with a total depth of 5 
μm and a 63X (1.40 NA) Plan-Apochromat oil-immersion objective. Images and scale 
bars were generated with Zeiss ZEN Confocal Software (Carl Zeiss MicroImaging 
GmbH, Jena, Germany). For immunofluorescence analysis and quantification, final 
images were generated using Adobe Photoshop CS4, version 11.0. Quantifications 
were performed from multichannel images obtained using a 63 × objective using 
ImageJ, marking either the cell perimeter or the nucleus as the region of interest and 
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50 cells were analysed for each data set. The obtained mean value was used to 
compare experimental groups.
4.6. siRNAs and transfection
The knockdown ANXA1 proteins in HUVEC cells was performed using small 
interfering RNA (siRNAs) targeting human ANXA1 proteins as reported in [14]. All 
siRNAs were purchased from IDT (Integrated DNA Technologies Inc., Coralville, IA). 
The duplex sequences to target ANXA1 were: (a) sense 5′‐GCU AUG AUC AGA AGA 
CUU UAA UAA T‐3′ and antisense 3′‐UUC GAU ACU AGU CUU CUG AAA UUA 
AUA‐5′; (b) sense 5′‐GUU GUU UUA GCU CUG CUAAAA ACT C‐3′ and antisense 
3′‐UCC AAC AAA AUC GAG ACG AUU UUU GAG‐5′; (c) sense 5′‐AAG UAC AGU 
AAG CAU GAC AUG AAC A‐3′ and antisense 3′‐GGU UCA UGU CAU UCG UAC UGU 
ACU UGU‐5′. siRNA Oligo‐Scrambled (Santa Cruz Biotechnology) was used as control 
at the same concentration. HUVEC cells were initially plated in media containing 10% 
FBS. After 24 hours, the cells were washed once with PBS and transfected or not with 
siRNAs by Lipofectamine 2000 (ThermoFisher Scientific; Waltham, MA, USA) 
according to the manufacturer's instructions. The cells were processed for western blot 
analysis at 48 hours after transfection. The administration of mesoglycan and/or VEGF 
was performed 24 hours after the transfection.
4.7. EVs isolation
HUVEC cells (about 2 × 106 cells) were incubated for 24 hours in EGM-2 (DMEM, 
Euroclone, Milan, Italy) without FBS treated or not with mesoglycan (0.3 mg/ml). Then, 
the supernatant was centrifuged at 4,400xg at 4°C for 15 minutes to pellet death cells, 
followed by a second centrifugation at 13,000xg at 4°C for 2 minutes to remove 
apoptotic bodies. EVs were enriched by centrifuging at 20,000xg at 4°C for 30 minutes, 
the supernatant was removed, and pellets were re-suspended in the selected buffers. 
The buffer we chose for the resuspension was 100 μl PBS for the administration to cells 
and nanoparticle tracking analysis 30 μl RIPA lysis buffer to perform Bradford assay. All 
analyses were performed on fresh isolated fractions.
4.8. Nanoparticle tracking analysis for sizing EVs
Approximately 0.5 mL of EVs (between 106 to 109 vesicles) in suspension were 
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(Malvern Instruments Ltd., Malvern, UK); five videos of 90 seconds each were recorded 
for each sample. Data analysis was performed with NTA2.1 software (Nanosight, 
Malvern, UK). Software settings for analysis were the following, Detection Threshold: 
5–10; Blur: auto; Minimum expected particle size: 20 nm.
4.9. ELISA for VEGF-A
After treatments with mesoglycan and siRNA against ANXA1, HUVEC supernatants 
were collected and the secreted VEGF-A amount was quantified through the Human 
VEGF-A ELISA kit, following the manufacturer’s instructions (Invitrogen, Carlsbad, 
California, USA).
4.10. Statistical analysis
All results are the mean ± S.E.M. (Standard Error of Mean) of at least 3 experiments 
performed in triplicate. Statistical comparisons between groups were made using 
one‐way ANOVA comparing two variables and two-way ANOVA to compare 
experimental groups. ANOVA test was followed by the Tukey's multiple comparisons 
test. Differences were considered significant if p<0.05, p<0.01 and p<0.001.
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Fig. 1. Evaluation of migration and tube formation of endothelial cells in response to 
VEGF-A and mesoglycan (A) Representative images of scratch wound migration assays at the 
times indicated. Cells were treated with either Mesoglycan (0.3mg/ml), VEGF-A (10ng/ml) or a 
combination of the two. Scale bar = 150 μm. (B) The rate of Cell migration was determined by 
measuring the wound closure by individual cells from the initial time (0 h) to the selected time-
points (24 h). Magnification 10 ×. (C) Representative images of tube formation by HUVEC cells 
seeded for 12 h on matrigel and EBM2 1:1 and in presence or absence of mesoglycan (0.3 
mg/mL), VEGF-A (10ng/mL), mesoglycan (0.3 mg/mL) and VEGF-A (10ng/mL). Scale 
bar = 100 μm. Analysis of (D) tube length and (E) number of branches calculated by ImageJ 
(Angiogenesis Analyzer tool) software. The data represent a mean of three independent 
experiments ± SEM. * p <0.05 for all treatments vs. untreated cells. # p <0.05 for all treatments 
vs. mesoglycan. @ p < 0.05 for all treatments vs. VEGF-A treatment.
Fig. 2 Analysis of VEGFR2 pathway in HUVEC cells (A) Western blot analysis and (B) 
quantification of total protein extracts from endothelial cells treated for 24 h with mesoglycan (0.3 
mg/mL), VEGF-A (10ng/mL) or mesoglycan (0.3 mg/mL) and VEGF-A (10ng/mL) in combination. 
Cropped blots from full‐length gels are representative of n = 3 independent experiments with 
similar results using antibodies against VEGFR2, p-VEGFR2, ERK, p-ERK, p38MAPK, p-HSP27, 
FAK, p-FAK and normalized with GAPDH. The blots were exposed to Las4000 (GE Healthcare 
Life Sciences). The data represent a mean of three independent experiments ± SEM. * p <0.05 
for all treatments vs. untreated cells. # p <0.05 for all treatments vs. mesoglycan. @ p < 0.05 for 
all treatments vs. VEGF-A treatment (C) Immunofluorescence analysis of HUVEC cells in 
presence or not of mesoglycan (0.3 mg/mL), VEGF-A (10ng/mL) and mesoglycan (0.3 mg/mL) 
and VEGF-A (10ng/mL) co-administrated. The cells were fixed and labelled with antibody against 
p-VEGFR2 (panels a-d), VE-cadherin (panels e-h), FAK (panels m-p, and relative 4× zoom) and 
with phalloidin (panels i-l). Nuclei were stained with Hoechst 33342 1:1000 for 30 min. at room 
temperature (RT) in the dark. Magnification 63× 1.4 NA. Scale bar = 50 μm. (D) Fluorescence 
intensity for p-VEGFR2, VE-cadherin, F-actin and FAK signals on HUVEC cells using ImageJ 
software. The measurements are determined on ten field images from a single coverslip and 
randomly selected for three coverslips. * p < 0.05, vs. untreated control; # p <0.05 for all 
treatments vs. mesoglycan. @ p < 0.05 for all treatments vs. VEGF-A treatment.
Fig. 3 Evaluation of MLEC WT and Sdc4-/- motility (A) Representative images of migration 
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VEGF-A (10ng/mL), mesoglycan (0.3 mg/mL) and VEGF-A (10ng/mL) co-administered. Scale 
bar = 150 μm. (B) Quantification of EC migration. Magnification 10 ×. (C) Representative images 
of tube formation by MLECs from WT and Sdc4-/- seeded for 12 h on matrigel and MLEC 
medium 1:1 treated with mesoglycan (0.3 mg/mL), VEGF-A (10ng/mL), mesoglycan (0.3 mg/mL) 
and VEGF-A (10ng/mL) together. Scale bar = 100 μm. Analysis of (D) tube length and (E) 
number of branches calculated by ImageJ (Angiogenesis Analyzer tool) software. The data 
represent a mean of three independent experiments ± SEM. * p <0.05 for all treatments vs. 
untreated cells. # p <0.05 for all treatments vs. mesoglycan. @ p < 0.05 for all treatments vs. 
VEGF-A. ^ p < 0.05 for Sdc4-/- treatment vs WT treatment.
Fig. 4 Effect of the absence of SDC4 in VEGFR2 pathway (A) Western blot and (B) 
quantization of protein extracts from MLEC WT and Sdc4-/- treated or not for 24 hr. with 
mesoglycan (0.3 mg/mL), VEGF-A (10ng/mL) and mesoglycan (0.3 mg/mL) and VEGF-A 
(10ng/mL) co-administered. * p < 0.05 for all treatments vs. untreated cells. # p<005 for all 
treatments vs. mesoglycan. @ p < 0.05 for all treatments vs. VEGF-A. ^ p < 0.05 for Sdc4-/- 
treatment vs WT treatment. (C) Immunofluorescence analysis of MLEC WT and Sdc4-/- in 
presence or not of mesoglycan (0.3 mg/mL), VEGF-A (10ng/mL) and mesoglycan (0.3 mg/mL) 
and VEGF-A (10ng/mL) together. The cells were fixed and labelled with antibody against p-
VEGFR2 (panels a-h), VE-cadherin (panels i-p), FAK (panels y-f’, and relative 4x zoom) and with 
phalloidin (panels q-x). Nuclei were stained with Hoechst 33342 1:1000 for 30 min. at room 
temperature (RT) in the dark. Magnification 63× 1.4 NA. Scale bar = 50 μm. (D) Fluorescence 
intensity for p-VEGFR2, VE-cadherin, F-actin and FAK signals on MLEC WT and Sdc4-/- cells 
using ImageJ software. The measurements are determined on ten field images from a single 
coverslip and randomly selected for three coverslips. * p < 0.05, vs. untreated control.
Fig. 5 Evaluation of the ANXA1‐mediated effects on mesoglycan-VEGF-A treatment on 
HUVEC motility (A) Western blot and (B) analysis for ANXA1 of total protein extract from 
HUVEC cells treated or not with mesoglycan (0.3 mg/mL), VEGF-A (10ng/mL), mesoglycan (0.3 
mg/mL) and VEGF-A (10ng/mL) together, HUVEC treated or not with siANXA1 (100 nM; 48hr.) 
and/or mesoglycan (0.3 mg/mL; 24hr.), VEGF-A (10ng/mL; 24hr.), mesoglycan (0.3 mg/mL; 
24hr.) and VEGF-A (10ng/mL; 24hr.) co-administered. The shown blots normalized using β-actin, 
are representative of n = 3 experiments with similar results. * p <0.05 for all treatments vs. 
untreated cells. # p <0.05 for all treatments vs. mesoglycan. @ p < 0.05 for all treatments vs. 
VEGF-A treatment (C) Representative bright field images captured of HUVEC cells (Scale bar = 
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wounds treated or not with mesoglycan (0.3 mg/mL; 24hr.), VEGF-A (10ng/mL; 24hr.), 
mesoglycan (0.3 mg/mL; 24hr.) and VEGF-A (10ng/mL; 24hr.) together and/or with siANXA1(100 
nM; 48hr.). Magnification 10×. (E) Representative images of tube formation by HUVEC seeded 
for 12 h on matrigel and EBM2 medium 1:1 and in presence or not of mesoglycan (0.3 mg/mL; 
24hr.), VEGF-A (10ng/mL; 24hr.), mesoglycan (0.3 mg/mL; 24hr.) and VEGF-A (10ng/mL; 24hr.) 
together and/or with siANXA1(100 nM; 48hr.). Scale bar = 100 μm. Analysis of (F) tube length 
and (G) number of branches calculated by ImageJ (Angiogenesis Analyzer tool) software. The 
data represent a mean of three independent experiments ± SEM. * p < 0.05 for all treatments vs. 
untreated cells. # p < 0.05 for all treatments vs. mesoglycan. @ p < 0.05 for all treatments vs. 
VEGF-A. ^ p < 0.05 for all siANXA1 treatments vs respective controls. (H) Western blot for VEGF-
A of supernatant from HUVEC cells treated or not with mesoglycan (0.3 mg/mL) and/or siANXA1. 
Protein normalization and the check of the sample quality were performed on β-actin and 
ponceau levels. The same experimental points have been analyzed by ELISA test (I) evaluating 
supernatants of HUVEC cells. The data represent a mean of three independent experiments ± 
SEM. * p < 0.05 for all treatments vs. untreated cells. # p < 0.05 for all treatments vs. 
mesoglycan. ^ p < 0.05 for all siANXA1 treatments vs respective controls.  
Fig. 6 Evaluation of EVs released from HUVEC cells (A) comparison of EVs released from 
HUVEC cells treated (green line) or not (red line) with mesoglycan (0.3 mg/mL) by Nanoparticle 
tracking analysis. (B) Western blot analysis of total protein extracts from HUVEC cells treated or 
not for 24 h with mesoglycan (0.3 mg/mL) and from EVs released by the same HUVECs. 
Cropped blots from full‐length gels are representative of n = 3 independent experiments with 
similar results using antibodies against CD81, CD63, ANXA1 and normalized with β-actin. The 
blots were exposed to Las4000 (GE Healthcare Life Sciences). 
Fig. 7 EVs interact via ANXA1/FPRs in autocrine manner (A) Bright field images (scale 
bar = 150 μm) and (B) histogram of wound healing assay of HUVEC cells treated or not with EVs 
ctrl (1x106), EVs mesoglycan (1x106), BOC1 (100 μM) and/or their association. (C) 
Representative images of analysed fields of tube formation assay by HUVEC seeded for 12 h on 
matrigel and EBM2 medium 1:1 and in presence or not of EVs ctrl (1x106), EVs mesoglycan 
(1x106) and/or BOC1 (100 μM). Magnification 20×. Scale bar = 150 μm. Analysis of (D) tube 
length and (E) number of branches calculated by ImageJ (Angiogenesis Analyzer tool) software. 
The data represent a mean of three independent experiments ± SEM. * p < 0.05 for all treatments 
vs. untreated cells. § p < 0.05 for all treatment vs. EVs ctrl. ~ p < 0.05 for all treatments vs. EVs 
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Fig. 8 Analysis of EndMT markers on HUVEC cells treated or not with EVs and BOC1. 
Immunofluorescence analysis of endothelial cells in presence or not of EVs ctrl (1x106), EVs 
mesoglycan (1x106), BOC1 (100 μM) and vesicles and BOC1 (100 μM) together. The cells were 
fixed and labelled with antibody against VE-cadherin (panels a-f), fibronectin (panels m-r), FAK 
(panels s-x, and relative ×4 zoom) and with phalloidin (panels g-l). Nuclei were stained with 
Hoechst 33342 1:1000 for 30 min. at room temperature (RT) in the dark. Magnification 63× 1.4 
NA. Scale bar = 50 μm. (B) Fluorescence intensity for p-VEGFR2, VE-cadherin, F-actin, FAK and 
fibronectin signals on HUVEC cells using ImageJ software. The measurements are determined 
on ten field images from a single coverslip and randomly selected for three coverslips. * p < 0.05, 
vs. untreated control. 
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